文献速递前列腺增生与排尿功能障碍男科与性医学

5α还原酶抑制剂与男性乳腺疾病及勃起功能障碍的关联:TriNetX数据库回顾性队列研究

The Association of 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia With Development of Male Breast Disease and Erectile Dysfunction: A Retrospective Cohort Study of TriNetX Database.
PubMed 文献 · Urology · 2026-08-24

基于TriNetX数据库的回顾性队列研究,经倾向评分匹配后5ARI组与非5ARI组各550622例,中位随访约2.95年。5ARI使用与男性乳腺癌风险无显著增加相关(RR 1.09;95%CI 0.94-1.27),但与男性乳腺发育(RR 1.55;95%CI 1.49-1.62)和勃起功能障碍(RR 1.17;95%CI 1.15-1.18)风险增加相关。

要点

  • 5ARI使用未增加男性乳腺癌风险(RR 1.09;95%CI 0.94-1.27)。
  • 5ARI使用与男性乳腺发育风险增加相关(RR 1.55;95%CI 1.49-1.62)。
  • 5ARI使用与勃起功能障碍风险增加相关(RR 1.17;95%CI 1.15-1.18)。

核心结论

  • 5ARI使用未增加男性乳腺癌风险,但与男性乳腺发育和勃起功能障碍风险增加相关。

研究设计与样本

  • 回顾性队列研究,查询TriNetX研究网络数据库,暴露为5ARI,经倾向评分匹配人口学特征、合并症和男性乳腺癌风险因素。
  • 匹配前5ARI组553628例、非5ARI组2729063例,匹配后每组550622例。
  • 5ARI组中位随访2.95年(IQR 5.14年),非5ARI组中位随访2.94年(IQR 5.44年)。

主要发现

  • 5ARI队列与男性乳腺癌风险增加无关(RR 1.09;95%CI 0.94-1.27)。
  • 5ARI使用与男性乳腺发育风险增加相关(RR 1.55;95%CI 1.49-1.62)。
  • 5ARI使用与勃起功能障碍风险增加相关(RR 1.17;95%CI 1.15-1.18)。
  • 亚组分析中,非那雄胺(RR 1.12;95%CI 0.96-1.32)和度他雄胺(RR 0.94;95%CI 0.67-1.32)均与男性乳腺癌无关。
  • 非那雄胺和度他雄胺均与男性乳腺发育和勃起功能障碍风险增加相关,度他雄胺关联更强(乳腺发育:RR 2.13,95%CI 1.92-2.35;ED:RR 1.40,95%CI 1.35-1.45),非那雄胺(乳腺发育:RR 1.48,95%CI 1.42-1.54;ED:RR 1.14,95%CI 1.12-1.15)。

临床怎么用

  • 对接受5ARI治疗的BPH患者,应告知男性乳腺发育和勃起功能障碍风险增加,尤其使用度他雄胺时。
  • 5ARI使用未显示增加男性乳腺癌风险,但仍需结合个体风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association of 5-α reductase inhibitors (5ARIs; finasteride and dutasteride) with male breast cancer (MBC), gynecomastia, and erectile dysfunction (ED) among men treated for benign prostatic hyperplasia (BPH). METHODS: We queried the TriNetX database-Research Network. The exposure of interest was 5ARI. We propensity score matched (PSM) for demographic features, comorbidities, and MBC risk factors. Outcomes included risk of MBC, gynecomastia and ED. RESULTS: 5-ARI cohort (N = 553,628) and non-5ARI cohort (N = 2,729,063) before PSM and 550,622 patients in each cohort after. Follow-up of median 2.95 years and interquartile range (IQR) of 5.14 years in the 5ARI cohort versus median 2.94 years (IQR:5.44) in the non-5ARI cohort. Patients in the 5ARI cohort were not associated with a increased risk of MBC (RR 1.09; 95%CI:0.94-1.27). There was an increased risk of gynecomastia (RR 1.55, 95%CI:1.49-1.62) and ED (RR 1.17, 95%CI:1.15-1.18) associated with the use of 5ARI. On subgroup analysis, both finasteride (RR 1.12; 95%CI: 0.96-1.32) and dutasteride (RR 0.94; 95%CI: 0.67-1.32) were not associated with MBC. Both finasteride and dutasteride were associated with an increased risk of gynecomastia and ED, with stronger associations observed for dutasteride (gynecomastia: RR 2.13, 95% CI:1.92-2.35; ED: RR 1.40, 95% CI:1.35-1.45) than finasteride (gynecomastia: RR 1.48, 95% CI:1.42-1.54; ED: RR 1.14, 95% CI:1.12-1.15). CONCLUSION: In this multi-institutional retrospective cohort study, we did not find an increased risk of MBC associated with 5ARI use.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Titus RS, Bhatia A, Lozano VE, et al. The Association of 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia With Development of Male Breast Disease and Erectile Dysfunction: A Retrospective Cohort Study of TriNetX Database. Urology. 2026. PMID: 42637099. doi:10.1016/j.urology.2026.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。